In the United States, lung cancer is the second most common diagnosed cancer and the
leading cause of cancer-related death. Although tobacco smoking is the major risk factor …

Research on biomarker-driven therapy and immune check-point blockade in non-small cell
lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also …

Background A substantial proportion of patients with unresectable stage III non-small-cell
lung cancer (NSCLC) cannot either tolerate or access concurrent chemoradiotherapy, so …

Importance Administration of pembrolizumab plus concurrent chemoradiation therapy
(cCRT) may provide treatment benefit to patients with locally advanced, stage III non–small …

Introduction Adjuvant chemotherapy is recommended in patients with resected stages II to
IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA …

The TNM classification of malignant tumours is a mainstay tool in clinical practice and
research for prognostic assessment of patients, treatment allocation and trial enrolment, as …

Lung cancer, the leading cause of cancer death worldwide, is most frequently detected
through imaging tests. In this study, we investigated serum microRNAs (miRNAs) as a …

Molecularly targeted therapies and immune checkpoint inhibitors have markedly improved
the therapeutic management of advanced lung cancer. However, it still remains the leading …

Background Methyltransferase like 3 (METTL3) is an RNA methyltransferase implicated in
mRNA biogenesis, decay, and translation control through N6-methyladenosine (m6A) …

Background: Recent studies have demonstrated the predictive value of pretreatment
neutrophil-to-lymphocyte ratio (NLR) in advanced cancers; however, the role of NLR in …